PMID- 21802763
OWN - NLM
STAT- MEDLINE
DCOM- 20120424
LR  - 20211203
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 75
IP  - 2
DP  - 2012 Feb
TI  - Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are 
      poor prognostic factors in early stage NSCLC: a verification study.
PG  - 217-22
LID - 10.1016/j.lungcan.2011.06.012 [doi]
AB  - BACKGROUND: A recent study by Dhillon et al. [12], identified both angioinvasion 
      and mTOR as prognostic biomarkers for poor survival in early stage NSCLC. The aim 
      of this study was to verify the above study by examining the angioinvasion and 
      mTOR expression profile in a cohort of early stage NSCLC patients and correlate 
      the results to patient clinico-pathological data and survival. METHODS: 
      Angioinvasion was routinely recorded by the pathologist at the initial assessment 
      of the tumor following resection. mTOR was evaluated in 141 early stage (IA-IIB) 
      NSCLC patients (67 - squamous; 60 - adenocarcinoma; 14 - others) using 
      immunohistochemistry (IHC) analysis with an immunohistochemical score (IHS) 
      calculated (% positive cellsxstaining intensity). Intensity was scored as 
      follows: 0 (negative); 1+ (weak); 2+ (moderate); 3+ (strong). The range of scores 
      was 0-300. Based on the previous study a cut-off score of 30 was used to define 
      positive versus negative patients. The impact of angioinvasion and mTOR 
      expression on prognosis was then evaluated. RESULTS: 101 of the 141 tumors 
      studied expressed mTOR. There was no difference in mTOR expression between 
      squamous cell carcinoma and adenocarcinoma. Angioinvasion (p=0.024) and mTOR 
      staining (p=0.048) were significant univariate predictors of poor survival. Both 
      remained significant after multivariate analysis (p=0.037 and p=0.020, 
      respectively). CONCLUSIONS: Our findings verify angioinvasion and mTOR expression 
      as new biomarkers for poor outcome in patients with early stage NSCLC. mTOR 
      expressing patients may benefit from novel therapies targeting the mTOR survival 
      pathway.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Gately, K
AU  - Gately K
AD  - Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity 
      College Dublin, St. James's Hospital, Dublin 8, Ireland. kgately@stjames.ie
FAU - Al-Alao, B
AU  - Al-Alao B
FAU - T Dhillon
AU  - T Dhillon
FAU - Mauri, F
AU  - Mauri F
FAU - Cuffe, S
AU  - Cuffe S
FAU - Seckl, M
AU  - Seckl M
FAU - O'Byrne, K
AU  - O'Byrne K
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110730
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Vessels/pathology
MH  - Carcinoma, Non-Small-Cell Lung/chemistry/*mortality/pathology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/chemistry/*mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - TOR Serine-Threonine Kinases/*analysis/physiology
EDAT- 2011/08/02 06:00
MHDA- 2012/04/25 06:00
CRDT- 2011/08/02 06:00
PHST- 2011/02/28 00:00 [received]
PHST- 2011/06/04 00:00 [revised]
PHST- 2011/06/27 00:00 [accepted]
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2012/04/25 06:00 [medline]
AID - S0169-5002(11)00343-6 [pii]
AID - 10.1016/j.lungcan.2011.06.012 [doi]
PST - ppublish
SO  - Lung Cancer. 2012 Feb;75(2):217-22. doi: 10.1016/j.lungcan.2011.06.012. Epub 2011 
      Jul 30.